VALENCIA, Spain, May 27, 2026
ARTHEx Biotech, a clinical-stage biotechnology company focused on RNA-based therapeutics for neuromuscular diseases, has presented multiple scientific and clinical updates at the 15th International Myotonic Dystrophy Consortium (IDMC-15) meeting in Saguenay, Canada. The presentations highlighted the ongoing clinical progress of ATX-01, the company’s investigational anti-miR therapy for Myotonic Dystrophy Type 1 (DM1), while also unveiling new mechanistic findings supporting the therapy’s potential application in Myotonic Dystrophy Type 2 (DM2). The data reinforce growing industry interest in RNA-targeted medicines designed to address the underlying molecular drivers of rare neuromuscular disorders.
ARTHEx Biotech stated that the latest findings strengthen scientific confidence in ATX-01’s ability to deliver disease-modifying benefits across multiple manifestations of myotonic dystrophy. The company’s lead therapeutic candidate is designed to inhibit miR-23b, a microRNA increasingly recognized as a key contributor to the RNA-driven pathology underlying DM1 and DM2. Researchers believe targeting this pathway may help restore normal cellular function, improve RNA splicing abnormalities, and reduce toxic RNA accumulation that drives progressive muscle dysfunction in affected patients.
ATX-01 Shows Encouraging Clinical Progress in DM1
One of the primary presentations at IDMC-15 focused on preliminary clinical findings from the ongoing ArthemiR™ Phase I/IIa trial, a randomized, double-blind, placebo-controlled first-in-human study evaluating ATX-01 in adult patients with DM1. The trial is currently being conducted across 12 clinical sites in Canada, France, Italy, the Netherlands, Spain, the United Kingdom, and the United States. According to the company, the study is assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy of ascending single and multiple doses of the therapy.
ARTHEx Biotech reported that ATX-01 has so far demonstrated a favorable safety and tolerability profile across the first dose levels evaluated. Investigators observed no dose-limiting toxicities during early dose escalation cohorts, and the study continues progressing into higher dose evaluations. Additional analyses involving muscle biopsies, MBNL protein levels, and DMPK RNA levels are expected later during the study’s next stages.
Advertisement
Frédéric Legros, Executive Chairman and Chief Executive Officer of ARTHEx Biotech, stated that the growing body of clinical data supports the company’s belief that targeting miR-23b may deliver meaningful disease-modifying effects for patients with myotonic dystrophy. He also emphasized that the latest findings extend the company’s scientific platform beyond DM1 and open potential future opportunities for patients with DM2, an area with substantial unmet medical need.
Mechanistic Data Strengthen RNA Therapeutic Potential
Additional presentations delivered at IDMC-15 explored the molecular mechanisms underlying ATX-01’s therapeutic activity. Researchers reported that miR-23b is significantly upregulated in muscle biopsies from DM1 patients and correlates with disease severity markers. According to the findings, ATX-01 exerts a dual mechanism of action by simultaneously restoring MBNL1 protein expression while promoting degradation of toxic DMPK RNA, leading to improved RNA splicing regulation and broader correction of disease-associated molecular abnormalities.
Scientists involved in the research stated that compared with direct DMPK-targeting approaches, ATX-01 may provide broader molecular rescue by restoring MBNL activity across multiple biological pathways associated with muscle development and function. Researchers believe this broader mechanism may help improve therapeutic outcomes across the multisystem manifestations commonly associated with myotonic dystrophy.
ARTHEx Expands Research Into DM2 Therapeutics
A third presentation introduced new preclinical findings supporting the potential use of ATX-01 in Myotonic Dystrophy Type 2, a rare multisystem neuromuscular disease for which no approved therapies currently exist. Researchers reported that inhibition of miR-23b restored MBNL-dependent RNA processing in DM2 cellular models and corrected multiple disease-associated splicing abnormalities without altering overall CNBP gene expression.
The findings provide early proof-of-concept evidence supporting anti-miR-23b therapy in DM2 and may significantly expand the future clinical and commercial potential of ARTHEx Biotech’s RNA therapeutic platform. Industry analysts believe RNA-targeting medicines represent one of the fastest-growing areas of biotechnology innovation as companies increasingly focus on therapies capable of directly addressing genetic and molecular drivers of disease.
The latest data presented at IDMC-15 further position ARTHEx Biotech among the emerging biotechnology companies advancing next-generation RNA therapeutics for rare neuromuscular diseases with significant unmet medical needs.
Source: ARTHEx Biotech press release
